BioCentury
ARTICLE | Clinical News

ISIS-SOD1Rx: Phase I data

April 8, 2013 7:00 AM UTC

A double-blind, placebo-controlled, U.S. Phase I trial in 32 familial ALS patients with SOD1 mutations showed that 0.15, 0.5, 1.5 and 3 mg doses of ISIS-SOD1Rx given as a continuous intrathecal infusi...